Hereditary Malignant Urinary System Neoplasm

Hereditary Malignant Urinary System Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

13 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 5
Recruiting: 3
Ph III recruiting: 0
Growth YoY: —
Industry share: 40%
Top sponsor: Jonsson Comprehensive Cancer Center
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (2)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01130519	A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer	completed	Phase 2	83	National Cancer Institute (NCI)NIH	1	Feb 21, 2025	clinicaltrials
NCT00971620	Randomized Pilot Study for the Treatment of Cutaneous Leiomyomas With Botulinum Toxin	completed	Phase 2	18	National Cancer Institute (NCI)NIH	1	Apr 7, 2017